Background: Asthma and allergic diseases are heterogeneous. Measurement of
| INTRODUCTION
There is increasing recognition that asthma is a heterogeneous condition, with multiple phenotypes. 1 The patterns of symptoms and associations with risk factors are likely to be different between these phenotypes, reflecting differences in aetiology, manifestations and the underlying pathophysiology. 2 Accurate characterization of these phenotypes may enable researchers to identify potential factors that predict the risk of developing specific forms of asthma and their prognosis in the long term. An assessment of airway biomarkers of adults with asthma may assist in differentiating between phenotypes. 3 The usefulness of oxidative stress biomarkers in the exhaled breath condensate (EBC) in this manner is a current topic of interest.
Nitric oxide (NO) is a biological mediator of eosinophilic 4 and neutrophilic inflammation 5 and has been implicated in the physiological regulation of the airways and pathophysiology of airway diseases. 4, 6 NO is enzymatically generated by nitric oxide synthase and then oxidized to nitrite and nitrate by several mechanisms, including macrophage activation. 7 Total nitric oxide products (NO x , nitrate and nitrite) are the more stable end-products of nitric oxide metabolism and can be detected in EBC. 8, 9 Recently, anti-IL-13 treatment has suggested that IL-13 is the predominant pathway affecting NO generation rather than eosinophils alone. 10 EBC samples the entire respiratory tract from the mouth to the alveoli, 7 and as such, the precise airway origin of each EBC marker is unknown. 11 Although many of the inflammatory markers are likely to come from the lower airways, some will also be generated from the larger and upper airways. 12 Several studies have examined the associations between oxidative stress biomarkers in EBC and asthma, 13, 14 but less is known about the associations between the levels of EBC biomarkers and rhinitis. 15 Moreover, atopic sensitization is strongly associated as a prelude to the development of allergic diseases, including asthma and rhinitis, which has given rise to the concept of the "unified airway." However, similar clinical allergic features can be initiated by different immune mechanisms, 16 and so it remains unclear whether NO-related biomarkers in EBC are uniformly associated with the presence and patterns of atopic sensitization.
EBC total nitric oxide products (NO x ) are increased in individuals with asthma compared to healthy individuals. 17, 18 Previous studies have had insufficient power to compare associations between allergic disease phenotypes and EBC NO x . In addition, most studies have been conducted in clinical populations with more severe disease, rather than population-based samples with a less severe spectrum of asthma, and likely very few truly severely affected individuals. Associations between inflammatory markers and asthma phenotypes may change with age as environmental triggers become increasingly important in later life. 7 It remains possible that the associations with EBC biomarkers may change with age, but this has not been examined in a single study using the same methods and we hypothesized that EBC NO x would be associated with all subsets of atopic disease. Therefore, using data from two prospective cohorts, we aimed to investigate the associations between the levels of NO x in EBC and (a) different allergic phenotypes of asthma, atopic sensitization and rhinitis; (b) lung function, bronchial hyperresponsiveness (BHR) and fraction of exhaled nitric oxide (FeNO); and (c) to assess whether these associations were consistent in young and middle-aged adults.
| METHODS

| Study population
Participants from two Australian longitudinal studies with different age groups were included (a) the Melbourne Atopy Cohort Study (MACS) (n = 424, mean (±SD) age: 17.8 ± 1.2 years, described throughout as the young group) 19 and (b) the Tasmanian Longitudinal Health Study (TAHS) (n = 794, mean age: 49.4 ± 0.5 years, described as the middle-aged group). 20 The MACS is a study of individuals with a family history of allergic diseases, whereas TAHS is a whole population study. The recruitment process and protocol for both studies have been described elsewhere. 19, 20 See Appendix S1
in the online data supplement for further details.
The MACS was initially approved by the Mercy Maternity Hospi- 
| Collection of EBC
EBC samples were collected from participants by following ATS/ERS protocols using an established method. 21, 22 After oral lavage, participants breathed tidally into a glass condenser via a one-way valve with saliva trap. EBC was collected using a custom-made glass-condensing device containing a thermal flask chilled with ice. Collection took between 15 and 20 minutes to obtain 0.4-3.0 mL of EBC. Each sample was deaerated with argon gas for 20 seconds, and then immediately frozen and stored at −80°C for later analysis. Storage times of the collected EBC samples were different between participants within each study and also between the two cohorts, which varied from 3.9 to 4.7 years, (see Table S1 in the online data supplement).
| Analysis of total nitric oxide products (NO x )
NO x concentration in EBC was measured after enzymatic reduction in nitrate using a fluorescent modification of the Griess method. See Appendix S1 in the online data supplement for the definitions used in this manuscript.
| Statistical methods
We found that about half of the participants had readings below the lower LOD (<2.50 μmol/L) for EBC NO x . Rather than exclude these participants, nondetectable values of EBC NO x were assigned to equal half the detection level (= 1.25 μmol/L). 24 The distribution of EBC NO x concentrations was highly right-skewed in both cohorts and could not be transformed to approximate normality. Therefore, cut-point levels of low (= 1.25 μmol/L), medium (1.26-19.9 μmol/L) and high (≥20.0 μmol/L) were selected, and ordinal logistic regression models were used to assess the associations between various allergic phenotypes (based on symptoms in the previous 12 months) as exposures and levels of EBC NO x as outcomes. All models met the proportional odds assumption for both overall group and subgroups and the parallel regression assumption, as assessed using the Brant test. Potential confounders were selected on the basis of current knowledge and/or biological plausibility. Some studies have suggested that levels of EBC biomarkers are directly associated with sex and age, 25, 26 and these variables should be considered as confounding factors when interpreting the results. 11 The duration of EBC sample storage between the sample collecting and analyses was also Meta-analyses were conducted in order to obtain the pooled estimates of associations across the MACS and TAHS cohorts when the heterogeneity of associations, as assessed by I 2 statistic, was <80%. 27 A fixed-effect model was used when the I 2 statistic was ≤30%, and a random-effect model was used when I 2 was more than 30%. All data were analysed using Stata software package, version 13.1 (StataCorp, College Station, TX, USA).
| RESULTS
| Characteristics of the study populations
In the MACS, 85.1% (n = 361) of participants provided an EBC sample at the 18-year follow-up compared to 56.9% (n = 452) of participants at the 5th-decade TAHS follow-up.
There was approximately an even sex distribution in both cohorts ( Table 1 ). As expected due to the inclusion criteria, the MACS cohort was younger and had more allergic disease than the TAHS cohort. Thus, the rate of atopic sensitization (and aero-sensitization) was higher in the MACS than the TAHS (67% vs 57%). Sensitization to house dust mite (HDM) was common in both cohorts, particularly MACS (63% vs 48% for TAHS). The proportion of participants who used ICS medication in the TAHS (12%) was slightly greater than that in the MACS (7%), as was current or ever having had rhinitis.
| Overall description of the EBC NO x values
Approximately half of the samples were above the lower limit of 
| Associations between current asthma, asthma phenotypes and EBC NO x
While current asthma in each cohort was associated with a nonsignificant trend for elevated levels of EBC NO x, when these results were pooled using meta-analysis, the odds of elevated EBC NO x level in participants with current asthma were significantly increased (OR = 1.57 [95% CI: 1.02,2.13], Table 2 ). EBC NO x values were higher in participants with current atopic asthma compared to the reference group with neither asthma nor atopy (Table 2) . Although there was no evidence of elevated levels of EBC NO x in nonatopic asthmatic participants, there were limited numbers of participants with this phenotype in both studies. There was an association between NO x and the atopic nonasthmatic phenotype in the TAHS cohort, but not the MACS cohort (I 2 = 71%, P-value of heterogeneity = 0.06, Table 2 ).
| Association between atopic sensitization and EBC NO x
In both cohorts, the odds of an elevated EBC NO x level were greater in those with atopic sensitization compared to those without atopic sensitization. The association was somewhat stronger in the TAHS than MACS (P-value of heterogeneity = 0.22) (see Table S2 in the online data supplement). This association was stronger in those with poly-aero-sensitization.
The associations between mono-aero-sensitization and levels of EBC NO x were substantially different between the two cohorts. In the TAHS, the odds of an elevated EBC NO x level were approximately 2.2-fold greater in participants with mono-aero-sensitization, when compared to those without atopic sensitization. In contrast, in the MACS cohort, there was no evidence of a significant association between mono-aero-sensitization and higher levels of NO x (P = 0.85). These differences did not appear to be due to the type of specific aeroallergens, since the vast majority of monosensitized participants in both studies were sensitized to HDM only (see Table S3 in the online data supplement). Interestingly, the median weal size to house dust mite in MACS monosensitized participants was greater In both the MACS and TAHS cohorts, we saw an approximately 3% increase in odds for every 1 mm in the sum of the SPT weals (for both MACS and TAHS OR = 1.03, 95% CI = 1.01-1.05).
| Associations between current rhinitis, rhinitis phenotypes and EBC NO x
EBC NO x was associated with current rhinitis in TAHS (Table 3 ), but not in MACS. Furthermore, in the TAHS only, the odds of an elevated EBC NO x level were higher in those participants with atopic nonrhinitis and also in those with atopic rhinitis, when compared to participants with neither atopy nor rhinitis. These associations were not observed in the MACS, and there was evidence that the associations differed between the two cohorts (I 2 = 70%) ( Table 3 ).
| Factors associated with EBC NO x levels
To identify independent factors associated with EBC NO x , we performed mutually adjusted regression models (adjusting for all variables under investigation). In both cohorts, the odds of an elevated EBC NO x level were greater in participants with poly-aero-sensitization (see Table S4 in the online data supplement). In the TAHS only, the odds of elevated EBC NO x level were greater in participants with mono-aero-sensitization, and there was evidence that this association differed between the two cohorts (I 2 = 65%) (see Table S4 in A total of 9 participants in the MACS and 7 participants TAHS were excluded due to missing survey data on sensitization status.
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To further explore any subgroup associations, all two-way interactions between each factor listed in Table S4 were assessed using likelihood ratio tests. The majority of these interactions were not statistically significant (P > 0.10) with few interactions being present only in the TAHS (Table 4) 
| EBC NO x and lung function, BHR and FeNO
In the MACS cohort, the prebronchodilator (BD) FEV 1 /FVC ratio decreased by 7% for each 1 μmol/L increase in EBC NO x (95% CI:
reduced from 1% to 13%, p = 0.04, see Table S5 in the online data supplement), while FEV 1 was not associated with NO x . These associ- Figure S5 in the online data supplement), there was evidence that this association was modified by aeroallergen sensitization status (P < 0.01).
While there was no evidence of an association in those with no or monosensitization, the association was stronger in those with polysensitization (β: 0.73 [95% CI: 0.23,1.23], p < 0.01).
| DISCUSSION
In this study of two adult cohorts of different ages, we found there was an association between atopy and higher levels of EBC NO x in both age groups, regardless of concurrent asthma or rhinitis. This association was stronger in those with poly-aero-sensitization in both cohorts. Increased levels of EBC NO x were related to decreased preand post-BD FEV 1 /FVC only in the young adults (MACS). There was no evidence of any significant association between increased concentrations of NO x and BHR. Most of the observed associations were consistent between young and middle-aged groups.
In both age groups, higher levels of EBC NO x were found in participants who had atopic sensitization. The underlying pathophysiology of atopic sensitization involves the activation of inflammatory cells and the release of inflammatory mediators. 28 In response to specific allergens, both airway epithelial cells and dendritic cells are stimulated to release various cytokines and thymic stromal lymphopoietin which activates mast cells, eosinophils and T H 2 cells in sensitized individuals. 28, 29 These mediators promote eosinophil infiltration and proliferation in the airway mucosa, mast cell degranulation and airway hyperresponsiveness. 30 Eosinophilic, IL-13-and IL-4-related airway inflammation are recognized as causing increased NO generation, elevated FeNO and hence increases the concentration of reactive nitrogen species and their potential contribution to oxidative stress. 31 We found that poly-aero-sensitization was associated with higher levels of EBC NO x, in both age groups. These findings suggest that an increased level of EBC NO x may be considered as a biological marker for the intensity of atopic sensitization in both young and middle-aged adults. It has been shown previously that sensitization to more than one allergen is associated with an increased risk of having asthma. 32 Interestingly, in the middle-aged group, this association was not seen in those who had used ICS in the previous 12 months, possibly indicating active suppression of NO x production.
The associations between current asthma or current rhinitis and EBC NO x were not as clear or as strong as those seen for sensitization in the combined data from both age groups. Although we had limited numbers of participants with asthma or rhinitis but without atopy, there was no evidence of elevated levels of NO x in these participants overall. This pattern of results suggests the most robust association between EBC NO x and asthma and rhinitis is predominantly due to the co-occurrence of allergic sensitization.
Interestingly, we found that elevated EBC NO x levels were associated with atopic nonasthma in the TAHS participants. It is possible that some of these participants had prior asthma leading to airway remodelling, 33 ongoing airway inflammation and elevated oxidative stress, 34, 35 but quite possibly, atopy may directly influence NO x , without requiring asthma to be intermediary step.
There was a significant association with allergic rhinitis and EBC NO x found in the TAHS cohort only. In contrast, nonatopic rhinitis showed no significant associations with the levels of EBC NO x in either study. It remains unclear why this is the case and may be due to the younger age of participants in MACS, or that all participants in this study have a family history of allergic disease.
The association between current asthma and EBC NO x observed in this study is relatively weak, when compared to previous studies. 18, 36, 37 This could be due to differences in the study populations or in the definitions of asthma, with others mostly studying more severe asthma. In previous studies, asthma was mainly defined according to clinical manifestations, physician diagnosis, responsiveness to bronchodilator drugs and/or measurements of pulmonary function. 15, 38 In the current study, in contrast, asthma was defined according to the questionnaire responses by the participants. Moreover, the use of different collecting devices to sample EBC or different analytical assays to measure NO x levels may also have created differences between studies. The type of collecting device clearly influences the levels of many EBC biomarkers, either by the amount of water vapour condensed or by the materials used in the condenser. 39, 40 In addition, the Griess method of measuring NO x may be limited in biological systems, and electrochemical methods may provide a more rapid method of analysis. 41 In epidemiological studies, collecting EBC at field sites may be more convenient and more practical than having NO analysis acutely available. 40, 42 Another recent study reported median values of~7.2 μmol/L 43 in middle-aged participants without respiratory disease, while the values we see in this study are lower (~1.5 μmol/L). This could be due to a range of factors, including the storage period resulting in reduced measurable levels, and the different device used (eg, glass condenser versus R-tube or other devices).
In this study, EBC NO x was influenced by the long period of storage. Despite being frozen at −80°C, it is likely that biomarkers were degraded during the storage period and so the duration of sample storage needs to be considered when analysing EBC biomarkers in future studies. A challenge for epidemiological studies, where large numbers of participants are recruited, is that recruitment takes time to complete, and rapid sample analysis would require multiple batches, which are costly and can itself cause errors due to batch-to-batch variation.
Additional longitudinal studies are required, where EBC biomarkers are measured repeatedly in the same participants, to determine whether changes in these biomarkers could predict subsequent exacerbations of airway inflammation and to determine the impact of 
| Strengths and limitations
The main strength of this study is that the associations were investigated within two large longitudinal cohorts. A large number of EBC samples from these cohorts were collected, which made it possible to compare and contrast the findings. In addition, the available data combined from both cohorts were used to identify different phenotypes of allergic airway diseases in order to evaluate the levels of While the results are based on prospective cohorts, these analyses are cross-sectional in nature, and this design gives no indication of the sequence of events. While we were able to assess associations with use of inhaled steroids in the previous 12 months, we did not have records of the time since last use, which should be explored in future. The MACS is a younger, high-risk allergy cohort, while the TAHS is a population-based cohort. There may be risk factors and pathways in the development of allergic disease and airway inflammation that are different between high-and normal-risk populations, which may explain some of the differences seen between the two cohorts. However, with some exceptions, the associations seen were largely similar between the two cohorts. Although both cohorts were conducted in Australia, the populations were recruited from different regions. The MACS participants represent young adults from an urban area (Melbourne), whereas the TAHS participants represent middle-aged adults from less urbanized area with a greater proportion living in a rural setting (Tasmania). Each population, therefore, was exposed to differing environmental factors such ALDAKHEEL ET AL.
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Validated questionnaires were used in both cohorts for defining current asthma, but lack of an objective definition is a potential limitation of this study, as is a lack of a consistent measure of asthma severity that could be used in both studies.
In conclusion, the current study demonstrates that atopy, rather than asthma or rhinitis, plays a key role in determining increased levels of EBC NO x . As this association was masked in the older participants who had ICS in the previous 12 months, it is also important to consider the prior use of medication. EBC is a noninvasive method that holds promise for detecting markers of inflammation that could be used to detect atopic diseases, and perhaps be able to monitor the effects of inhaled medication. Further studies are also needed, including the establishment of appropriate standardization
and reference values for biomarkers in EBC.
